1Cell.Ai and BioSkryb Announce Strategic Partnership to Advance Single Cell Multi-omics Innovation

Excerpt from the Press Release:

FOSTER CITY, Calif. and DURHAM, N.C., April 24, 2025 /PRNewswire/ — 1Cell.Ai, a global leader in single cell precision diagnostics, has joined forces with BioSkryb Genomics, a pioneer in single cell multi-omics, to co-develop and commercialize next-generation single cell multi-omic solutions. This collaboration will empower researchers and clinicians to detect and characterize rare mutations in single cells with unprecedented accuracy, facilitating breakthroughs in cancer research and enabling earlier detection and targeted therapy development.

Collaboration Details
This partnership merges BioSkryb’s single cell amplification and multi-omics chemistry with 1Cell.Ai’s OncoIncytes platform, creating a groundbreaking solution for analyzing rare cell populations such as circulating tumor cells (CTCs). With this integrated platform, researchers can now isolate CTCs at 1 in a billion, and characterize DNA, RNA, and protein targets from these individual single cells with unprecedented precision, significantly accelerating the development of advanced therapies, including antibody-drug conjugates (ADCs). Samples will be analyzed at both 1Cell.Ai’s CLIA laboratory in Foster City, California, and BioSkryb’s services laboratory in Durham, North Carolina.

Dr. James Rothman, Nobel Laureate and Board Member at 1Cell.Ai, remarked: “This collaboration represents a powerful synergy of visionary science and cutting-edge technologies. By integrating BioSkryb’s single cell multi-omics chemistry with 1Cell.Ai’s capabilities in single cell isolation and multi-omic profiling, we are opening new frontiers in understanding cellular behavior and disease mechanisms at an unprecedented level of clarity.”

Click the button below to read the entire Press Release:

Continue Reading The Press Release